Afrezza vs Insulin human

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 1 Diabetes

Shared mechanism: Insulin · full Type 1 Diabetes pipeline

Afrezza

Marketed by MannKind Corporation and partners

Approved in Type 1 Diabetespeptide
Partial signal

NCT04974528 · Phase 3 · completed

The study randomized 230 children and adolescents to mealtime Afrezza or to rapid-acting insulin injections, each with basal insulin; treatment was open-label rather than blinded. The primary endpoint was non-inferiority on HbA1c change at week 26, with a margin of 0.4 percentage points. The FDA label gives a difference of 0.18 percentage points (95% CI -0.07 to 0.44) and states that the primary endpoint of non-inferiority was not met. The figures are from the FDA label.

Next expected readout: March 2027 · NCT07224321 (registry estimate)

Reported efficacy

Change in HbA1c from baseline to week 26 (non-inferiority vs rapid-acting insulin analog, margin 0.4%): HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. (missed)

Result source: NCT04974528

Insulin human

Marketed by Eli Lilly

Approved in Type 1 Diabetes
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Type 1 Diabetes

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Insulin human: no structured comparison results are available for Type 1 Diabetes.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Afrezza

PP 2 h Excursion mg/dL 88.6 mg/dL @ 0.012wkDose 1
absolute value · mg/dL
No placebo or comparator arm
120 minutes PPGE
NCT04849845 · Phase 4 · registry result, not featured evidence
show 1 more result
36.9 mg/dL @ 0.012wkDose 2
120 minutes PPGE
NCT04849845 · Phase 4 · registry result, not featured evidence
HbA1c 0.435% @ 26wk
absolute change · percentage points
No placebo or comparator arm
NCT04974528 · Phase 3 · sponsor-reported, not registry data
Available safety results

Afrezza

Dropout rate
—Dose 1
NCT04849845 · Phase 4 · registry result, not featured evidence
show 3 more results
—Dose 2
NCT04849845 · Phase 4 · registry result, not featured evidence
—2 x 15 U
NCT00662857 · Phase 2 · registry result, not featured evidence
—1 x 30 U
NCT00662857 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Dose 1
NCT04849845 · Phase 4 · registry result, not featured evidence
show 3 more results
—Dose 2
NCT04849845 · Phase 4 · registry result, not featured evidence
—2 x 15 U
NCT00662857 · Phase 2 · registry result, not featured evidence
—1 x 30 U
NCT00662857 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Dose 1
NCT04849845 · Phase 4 · registry result, not featured evidence
show 3 more results
0%Dose 2
NCT04849845 · Phase 4 · registry result, not featured evidence
0%2 x 15 U
NCT00662857 · Phase 2 · registry result, not featured evidence
0%1 x 30 U
NCT00662857 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
Dose 1
cough 5%
NCT04849845 · Phase 4 · registry result, not featured evidence
show 3 more results
Dose 2
cough 10%
NCT04849845 · Phase 4 · registry result, not featured evidence
2 x 15 U
cough 14.8%
headache 7.4%
nausea 7.4%
NCT00662857 · Phase 2 · registry result, not featured evidence
1 x 30 U
cough 24.1%
headache 17.2%
hypoglycaemia 13.8%
NCT00662857 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afrezza's landscape · Insulin human's landscape